Published in FASEB J on December 30, 2005
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Sites of alkylation of human Keap1 by natural chemoprevention agents. J Am Soc Mass Spectrom (2007) 1.36
Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J Hematol Oncol (2009) 1.12
Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis. FEBS Lett (2007) 1.01
Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr (2011) 1.00
Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells. Anticancer Res (2010) 0.98
An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med (2013) 0.92
Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol. Invest New Drugs (2011) 0.85
Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets (2014) 0.83
Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Mol Med (2012) 0.83
Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-kappaB. Immunopharmacol Immunotoxicol (2009) 0.82
Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice. Mol Nutr Food Res (2013) 0.82
Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis. Int J Clin Exp Pathol (2012) 0.81
Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. Mol Cancer Ther (2015) 0.80
Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis (2010) 0.79
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma (2009) 0.79
Natural phenolic metabolites with anti-angiogenic properties - a review from the chemical point of view. Beilstein J Org Chem (2015) 0.78
Anticancer agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell proliferation. J Exp Ther Oncol (2012) 0.78
Evidence for the Effects of Xanthohumol in Disrupting Angiogenic, but not Stable Vessels. Int J Biomed Sci (2007) 0.78
The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. Front Physiol (2015) 0.78
Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation. Oncotarget (2016) 0.77
Xanthohumol, a Prenylated Flavonoid from Hops (Humulus lupulus), Prevents Platelet Activation in Human Platelets. Evid Based Complement Alternat Med (2012) 0.77
Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor. J Pharmacol Exp Ther (2010) 0.77
The involvement of xanthohumol in the expression of annexin in human malignant glioblastoma cells. Open Biochem J (2013) 0.75
Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. Cancer Sci (2017) 0.75
A 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) Domain. PLoS One (2016) 0.75
Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo. J Nat Prod (2017) 0.75
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis (2002) 2.08
Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res (2006) 1.96
Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87
Status and opportunities for genomics research with rainbow trout. Comp Biochem Physiol B Biochem Mol Biol (2002) 1.80
Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res (2005) 1.49
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene (2002) 1.44
Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J (2010) 1.42
CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol (2004) 1.40
Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol (2004) 1.28
Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response. J Immunol (2009) 1.25
Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J (2001) 1.21
HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol Lett (2003) 1.21
The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem (2007) 1.21
The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol (2004) 1.15
Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res (2004) 1.15
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 1.14
The 'chemoinvasion' assay, 25 years and still going strong: the use of reconstituted basement membranes to study cell invasion and angiogenesis. Curr Opin Cell Biol (2010) 1.11
The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther (2007) 1.10
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.09
Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS (2002) 1.08
The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia (2013) 1.02
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med (2013) 1.02
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer (2014) 1.02
The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis (2006) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
Neoplasia and neoplasm-associated lesions in laboratory colonies of zebrafish emphasizing key influences of diet and aquaculture system design. ILAR J (2012) 0.99
The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res (2005) 0.98
Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis (2002) 0.97
Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res (2005) 0.97
The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol (2002) 0.95
Angiopoietin2 and tie2: tied to lymphangiogenesis and lung metastasis. New perspectives in antimetastatic antiangiogenic therapy. J Natl Cancer Inst (2012) 0.95
Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res (2009) 0.94
Molecular pathways for cancer angioprevention. Clin Cancer Res (2007) 0.94
B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses. Antioxid Redox Signal (2010) 0.93
Marine sponge-derived polymeric alkylpyridinium salts as a novel tumor chemotherapeutic targeting the cholinergic system in lung tumors. Int J Oncol (2006) 0.92
Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis (2009) 0.92
Effect of xenoestrogen exposure on the expression of cytochrome P450 isoforms in rainbow trout liver. Environ Toxicol Chem (2002) 0.92
AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer (2007) 0.92
AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther (2004) 0.91
Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Int J Cancer (2011) 0.91
Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva. Toxicol Appl Pharmacol (2004) 0.90
Endothelial cell aging and apoptosis in prevention and disease: E-selectin expression and modulation as a model. Curr Pharm Des (2008) 0.90
Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol (2010) 0.90
Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci U S A (2010) 0.90
N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol (2003) 0.89
Role of MT1-MMP in the osteogenic differentiation. Bone (2008) 0.89
Effects of polyphenol extract from olive pomace on anoxia-induced endothelial dysfunction. Microvasc Res (2012) 0.89
Influence of TCDD on zebrafish CYP1B1 transcription during development. Toxicol Sci (2008) 0.88
Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res (2003) 0.88
The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability. Mol Cancer (2010) 0.87
Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med (2009) 0.87
cDNA-directed expression of a functional zebrafish CYP1A in yeast. Aquat Toxicol (2004) 0.86
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol (2011) 0.86
Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res (2005) 0.86
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol Cancer Ther (2008) 0.86
Dental identification by comparison of antemortem and postmortem dental radiographs: influence of operator qualifications and cognitive bias. Forensic Sci Int (2012) 0.86
Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis (2006) 0.85
Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate (2013) 0.84
The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration. Biochem Pharmacol (2012) 0.83
Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention. Cancer Treat Res (2014) 0.83
Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications. Mol Cancer Ther (2007) 0.83
Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Mol Med (2012) 0.83
Phenylthiourea as a weak activator of aryl hydrocarbon receptor inhibiting 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 transcription in zebrafish embryo. Biochem Pharmacol (2004) 0.83
Transcriptional control of cell density dependent regulation of matrix metalloproteinase and TIMP expression in breast cancer cell lines. Thromb Haemost (2005) 0.82
Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR. Cancer Lett (2012) 0.82
Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int J Cancer (2009) 0.82
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer (2009) 0.82
CYP1B1 knockdown does not alter synergistic developmental toxicity of polycyclic aromatic hydrocarbons in zebrafish (Danio rerio). Mar Environ Res (2008) 0.82
Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res (2009) 0.81
CYP3C1, the first member of a new cytochrome P450 subfamily found in zebrafish (Danio rerio). Biochem Biophys Res Commun (2005) 0.81
Human chorionic gonadotropin inhibits Kaposi's sarcoma associated angiogenesis, matrix metalloprotease activity, and tumor growth. Endocrinology (2002) 0.80
Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. Int J Oncol (2003) 0.80
Inhibition of peroxynitrite-mediated LDL oxidation by prenylated flavonoids: the alpha,beta-unsaturated keto functionality of 2'-hydroxychalcones as a novel antioxidant pharmacophore. Chem Res Toxicol (2003) 0.80
Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer (2009) 0.80
Cloning, tissue distribution, and functional studies of a new cytochrome P450 3A subfamily member, CYP3A45, from rainbow trout (Oncorhynchus mykiss) intestinal ceca. Arch Biochem Biophys (2003) 0.79
Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol Sci (2009) 0.79
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate (2011) 0.79
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. Surg Oncol (2007) 0.79
Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis (2010) 0.79
Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors. Breast Cancer Res Treat (2007) 0.78
Comparison of hepatic in vitro metabolism of the pyrrolizidine alkaloid senecionine in sheep and cattle. Am J Vet Res (2004) 0.78
In vivo isolation and characterization of stem cells with diverse phenotypes using growth factor impregnated biomatrices. PLoS One (2008) 0.78
Surface-activated chemical ionization-electrospray ionization source improves biomarker discovery with mass spectrometry. Rapid Commun Mass Spectrom (2012) 0.78